SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a…

C4 Therapeutics, Inc. · 8-K filed Aug 11, 2026 at 07:14 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 11, 2026 at 07:14 ET

C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the Street consensus of -$0.23 by 21.7%. Cash increased to $300.4M following a $33.5M ATM raise and $20M Roche upfront, extending runway to end 2028. Clinical progress remains on track with Phase 2 MOMENTUM enrollment expected to complete in Q1 2027 and data in 2H 2027.

  • Q2 2026 revenue $6.6M vs $6.5M YoY (up 2.7%)
  • Net loss $23.6M vs $26.0M YoY; EPS -$0.18 vs -$0.37 YoY
  • EPS beat consensus of -$0.23 by 21.7%
  • Cash $300.4M, up from $268.3M QoQ; runway to end 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access